UK Clinical Vaccine Network Conference 2022

Bringing together and showcasing the work of the UK clinical vaccine community, to facilitate co-operation and collaborate on future challenges.

Register now

It is with great excitement that we can announce this year’s Clinical Vaccine Network Conference will be held in person at the Royal College of Physicians, London.

Hosted on the 30th June, this event will cover a wide spectrum of issues in vaccine development, presentations on the latest research, and the future of vaccines.

Whilst this conference will be made available to join virtually we thoroughly recommend attending in person to not miss out on this excellent networking opportunity. There will be an array of UK healthcare professionals, and other relevant decision makers who have a specific interest in vaccine intervention in the patient pathway.

Please share the flyer for the event available here with your colleagues.

If you have any queries, or would like to enquire about sponsorship of this event, please contact: debbie@pagemedical.co.uk.

@CVN_UK

Seqirus has sponsored this conference but has had no input into the arrangements or the content except the session on “Improving Influenza Vaccine Uptake” which has specifically been sponsored and arranged by Seqirus.

To view the recordings from the online UK Clinical Vaccine Network Conference held in 2020 please click here Clinical Vaccines Network Virtual Conference 2020

Dr Matthew Duchars

Dr Duchars is an executive with over 30 years of experience in biotechnology and prior to joining the Vaccines Centre in 2019 he was the president of Genie BioLogic LLC a company specialising in providing strategic direction and technical advice for the development of medical countermeasures in the US.

Before 2018, he spent three years as a VP Product Development for Emergent Biosolutions, three years at United Therapeutics focused on developing host based antiviral small molecule drugs, five years as a Chief Scientific Officer initially for Avecia Vaccines and then for PharmAthene, when they purchased the vaccine business in 2008.

Dr Duchars has worked on a wide variety of vaccine and therapeutic platforms as well as medical countermeasures, for multiple indications including Anthrax, Plague, Ebola, Smallpox, Marburg, Dengue, Zika, Radiation and Chemical agents.

He has led the development of multiple biopharmaceutical products from pre-IND laboratory stages through GMP scale up, to their final validation at a commercial operating scale. His experience extends into the development of human clinical and animal model data for the licensure of products, using both conventional and the animal rule path, and has been an invited speaker at both biopharmaceutical and FDA-sponsored conferences and workshops.

Dr Duchars earned a BS in microbiology and a PhD in microbial physiology from the University of Sheffield.

Top